Back to Search
Start Over
Plerixafor plus granulocyte colony-stimulating factor improves the mobilization of hematopoietic stem cells in patients with non-Hodgkin lymphoma and low circulating peripheral blood CD34+ cells.
- Source :
-
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation [Biol Blood Marrow Transplant] 2013 Apr; Vol. 19 (4), pp. 670-5. Date of Electronic Publication: 2013 Jan 17. - Publication Year :
- 2013
-
Abstract
- Many institutions have adopted algorithms based on preapheresis circulating CD34+ cell counts to optimize the use of plerixafor. However, a circulating peripheral blood CD34+ cell threshold that predicts mobilization failure has not been defined. The superiority of plerixafor + granulocyte colony-stimulating factor (G-CSF) over placebo + G-CSF for hematopoietic stem cell mobilization and collection was shown for patients with non-Hodgkin lymphoma in a phase III, prospective, randomized, controlled study. The question remains as to which patients may benefit most from the use of plerixafor. In this post hoc retrospective analysis, mobilization outcomes were compared between the 2 treatment arms in patients stratified by peripheral blood CD34+ cell count (<5, 5 to 9, 10 to 14, 15 to 19, or ≥20 cells/μL) obtained before study treatment and apheresis. Compared with placebo plus G-CSF, plerixafor plus G-CSF significantly increased the peripheral blood CD34+ cells/μL over prior day levels in all 5 stratified groups. The probability of subsequent transplantation without a rescue mobilization was far greater in the plerixafor-treated patients for the lowest initial (day 4) peripheral blood CD34+ cells/μL groups (<5, 5 to 9, or 10 to 14). Engraftment and durability were the same for the 2 treatment groups for all strata, but the effect in the lower strata could be altered by the addition of cells from rescue mobilizations. These findings may provide insight into the optimal use of plerixafor in all patients undergoing stem cell mobilization.<br /> (Copyright © 2013 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.)
- Subjects :
- Adult
Aged
Antigens, CD34 immunology
Benzylamines
Blood Component Removal
CD4 Lymphocyte Count
Cyclams
Double-Blind Method
Female
Hematopoietic Stem Cells immunology
Hematopoietic Stem Cells pathology
Humans
Leukocytes, Mononuclear immunology
Leukocytes, Mononuclear pathology
Lymphoma, Non-Hodgkin immunology
Lymphoma, Non-Hodgkin pathology
Male
Middle Aged
Placebos
Transplantation, Autologous
Granulocyte Colony-Stimulating Factor pharmacology
Hematopoietic Stem Cell Mobilization
Hematopoietic Stem Cell Transplantation
Hematopoietic Stem Cells drug effects
Heterocyclic Compounds pharmacology
Leukocytes, Mononuclear drug effects
Lymphoma, Non-Hodgkin therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1523-6536
- Volume :
- 19
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
- Publication Type :
- Academic Journal
- Accession number :
- 23333777
- Full Text :
- https://doi.org/10.1016/j.bbmt.2013.01.005